[Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].

Emoxyl (ruboxyl) is a product of chemical modification of daunorubicin mediated by a stable free radical. The drug was given to 63 patients with different malignancies stages I-II. Inhibition of hemopoiesis (leukopenia and thrombocytopenia) was identified as the dose-limiting toxicity level.

[Comparative study of cytosolic proteins in normal and neoplastic ovaries by polyacrylamide electrophoresis].

The report discusses the data on cytoplasmic protein occurrence in ovarian tissue (106) obtained by polyacrylamide gel electrophoresis. They were identified in normal ovarian tissue (15), benign tumor (16), primary malignant tumor (55) and tumor tissue after chemotherapy (20). A band was detected in the area of molecular 36 cD in malignant epithelial tumor tissue which was not seen in either normal, benign tumor tissue or after successful chemotherapy.

[The probability of the carcinogenic risk of using nitrosomethylurea for treating cancer patients].

The results of nitrosomethylurea (NMU) chemotherapy in 12 patients suffering Hodgkin's disease were evaluated. Significant effect was seen in 73.3% with 54.